PAR

10.9%

24.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-21

First 21 Last

Share
Profile

Follow
Mozzarc

4,093 Posts.

6549

18/07/19

11:15

Post #: 39577686
Share

Originally posted by Gan_Gans: ↑

Nice thread to finally come out with my research into how Paradigm all started. All IMO - backed up with what I could find.

Doing this because a) I'm bored. b) there's been some concern in this forum about our 70 year old drug (PPS) up against new frontline stem cell treatments, and that it would be great to have some comparison between PPS and new stem cell treatments. This concern was brought up due to media coverage on a Melbourne Stem Cell clinic in April(ish).

What if I was able to prove to you there already has been direct laboratory research between PPS and Mesenchymel Stem Cells? And what if I was to tell you that this research happened in a stem cell companies laboratory?

In 2010, Paul Rennie was COO of Mesoblast. Graeme Kaufman held the Strategic Development role in Mesoblast (then EVP Finance and Corporate Strategy). Peter Ghosh was a Scientific Adviser to Mesoblast. Kevin Hollingsworth was Company Secretary to Mesoblast. (all per Linkedin, company reports etc.)

In 2010, a medical paper was authored by Peter Ghosh et. al. (including Mesoblasts founder, Prof Silviu Itescu) titled:

"Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells"

It was a lab test of how PPS in different concentrations influenced MSC's in proliferation and differentiation. It's conclusion:

"This is the first study to demonstrate that PPS promotes MPC proliferation and chondrogenesis, offering new strategies for cartilage regeneration and repair in osteoarthritic joints."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875662/

My bet is - it all started here. I can't find a medical paper written by them that pits their MSC's against PPS directly (but you wouldn't would you) but what it shows was PPS was being fooled around with people closely related in work to our founders in 2010.

Now, moving forward from here I can't describe exactly how Paul Rennie, Graeme Kaufman, Peter Ghosh and Kevin Hollingsworth formed Paradigm. All I know it that MSB didn't pursue IP on PPS, whilst in 2012 Paradigm was created to ring fence patent and IP on PPS for various new treatment conditions. PAR was floated on the ASX in 2015 - they spent 3 years on patent and IP.

I also note in the EOFY report from PAR that three of the new hires are from MSB clinical/regulatory affairs - Sharon Charles, Karla Knower, Michelle Coffey.

Interesting, isn't it? It's partly why I'm betting our 70 year old drug is a winner.

Expand

Yes very interesting..imagine that study was done in 2010. Its now 2019...I dont know how long it will be until we have a trial that is focused actually on cartilage regeneration...it would be one of the biggest break throughs.
Its one thing to have a good pain relief remedy..its also one thing to have some regression of BMEL...but its a total game changer to regenerate cartilage itself !?
Great find GG and thanks for bringing it to our attention.

PAR Price at posting: $1.68 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 4,048 more messages in this thread...

First 21 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 24.5¢		Change -0.030(10.9%)		Mkt cap ! $85.7M

Open	High	Low	Value	Volume
27.5¢	27.5¢	24.0¢	$429.9K	1.713M

Buyers (Bids)

No.	Vol.	Price($)
7	161991	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
25.5¢	29634	2

View Market Depth

No.	Vol.	Price($)
4	44751	0.245
5	58371	0.240
2	8088	0.235
4	79340	0.230
4	58888	0.225

Price($)	Vol.	No.
0.255	29634	2
0.260	14040	2
0.270	10200	4
0.275	64943	3
0.280	100000	1

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last 25.0¢		Change -0.030 ( 7.51 %)
Open	High	Low	Volume
27.0¢	27.0¢	23.5¢	433775
Last updated 15.57pm 03/05/2024 ?

PAR (ASX) Chart

research reports and media, page-21

Featured News

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Dancing to that same 70s tune, China, and why I'm backing gold

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Provident Aurum's off-market bid sends Sihayo shares soaring

Sold out signs go up for RIU Resources Roundup in Sydney

BPH Energy renews NT Bonaparte Basin permit

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Infini Resources gearing up for UAV geophys survey over Portland Creek

Car EV-olution accelerates Oz into pole position

Buyers (Bids)

Sellers (Offers)

Featured News

research reports and media, page-21

Featured News

Top Stories

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Dancing to that same 70s tune, China, and why I'm backing gold

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

Provident Aurum's off-market bid sends Sihayo shares soaring

Sold out signs go up for RIU Resources Roundup in Sydney

BPH Energy renews NT Bonaparte Basin permit

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Infini Resources gearing up for UAV geophys survey over Portland Creek

Car EV-olution accelerates Oz into pole position

Buyers (Bids)

Sellers (Offers)

Featured News